IP Library Granted Patent US 8,802,085
Granted Patent B2
US 8,802,085 · App. 13/693,346 · Granted Aug 12, 2014

Compositions for topical treatment of medical conditions including wounds and inflammation

Inventors: Stephen G. Carter (Andover, MA); Zhen Zhu (Andover, MA); Kanu Patel (Londonderry, NH); Diane L. Kozwich (Notthingham, NH)
Assignee: BioChemics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,085
App. No.
13/693,346
Granted
Aug 12, 2014
Kind
B2
Abstract

A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.

Claims (22)

1. A formulation for topical administration comprising a carrier and a combination of active ingredients consisting essentially of a retinoid and a blood vessel dilator, wherein the blood dilator is selected from the group consisting of methyl nicotinate, hexyl nicotinate, papaverine, tolazoline, acetylcholine, sodium nitroprusside, adenosine and a combination thereof.

2. A formulation for topical administration comprising a carrier and a combination of active ingredients consisting essentially of a retinoid, a blood vessel dilator, and an antioxidant, wherein the blood dilator is selected from the group consisting of methyl nicotinate, hexyl nicotinate, papaverine, tolazoline, acetylcholine, sodium nitroprusside, adenosine and a combination thereof.

3. A formulation for topical administration comprising a carrier and a combination of active ingredients consisting essentially of a retinoid, a blood vessel dilator, and a promoter of mitochondrial function, wherein the blood dilator is selected from the group consisting of methyl nicotinate, hexyl nicotinate, papaverine, tolazoline, acetylcholine, sodium nitroprusside, adenosine and a combination thereof.

4. A formulation for topical administration comprising a carrier and a combination of active ingredients consisting essentially of a retinoid, a blood vessel dilator, an antioxidant and a promoter of mitochondrial function, wherein the blood dilator is selected from the group consisting of methyl nicotinate, hexyl nicotinate, papaverine, tolazoline, acetylcholine, sodium nitroprusside, adenosine and a combination thereof.

5. A formulation according to claim 1 , wherein the retinoid is vitamin A retinal, 9-cis-retinoic acid, tretinoin, isotretinoin, etretinoin, or acitretin.

6. A formulation according to claim 5 , further comprising a fatty acid ester.

7. A formulation according to claim 6 , wherein the fatty acid ester is palmitate or oleate.

8. A formulation according to claim 1 , wherein the blood vessel dilator is methyl nicotinate.

9. A formulation according to claim 2 , wherein the antioxidant is selected from the group consisting of ascorbate, coenzyme Q10, and a tocopherol.

10. A formulation according to claim 3 , wherein the promoter of mitochondrial function is selected from the group consisting of L-carnitine and acetyl-L-carnitine.

11. A formulation according to claim 1 , wherein the active ingredients are contained in a patch adapted for timed-release activity.

12. A formulation according to claim 2 , wherein the active ingredients are contained in a patch adapted for timed-release activity.

13. A formulation according to claim 3 , wherein the active ingredients are contained in a patch adapted for timed-release activity.

14. A formulation according to claim 4 , wherein the active ingredients are contained in a patch adapted for timed-release activity.

15. A formulation according to claim 4 , wherein the promoter of mitochondrial function is selected from the group consisting of L-carnitine and acetyl-L-carnitine.

16. A formulation according to claim 1 , further comprising a fatty acid ester.

17. A formulation according to claim 2 , further comprising a fatty acid ester.

18. A formulation according to claim 3 , further comprising a fatty acid ester.

19. A formulation according to claim 4 , further comprising a fatty acid ester.

20. A formulation according to claim 18 , wherein the fatty acid ester is palmitate or oleate.

21. A formulation according to claim 19 , wherein the fatty acid ester is palmitate or oleate.

22. A formulation according to claim 4 , wherein the antioxidant is selected from the group consisting of ascorbate, coenzyme Q10, and a tocopherol.

Assignments (4)
BILL OF SALE AND COURT ORDER Recorded Apr 14, 2021
From: BIOCHEMICS, INC.
To: CONVERGENT DISTRIBUTORS OF TEXAS LLC
Reel/Frame 055927/0076 →
SECURITY INTEREST Recorded Sep 11, 2014
From: BIOCHEMICS, INC.
To: BIO STRATEGIES, LP
Reel/Frame 033726/0465 →
LIEN Recorded Jul 2, 2014
From: BIOCHEMICS, INC.
To: SUNSTEIN KANN MURPHY & TIMBERS LLP
Reel/Frame 033233/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2013
From: CARTER, STEPHEN G.; ZHU, ZHEN; PATEL, KANU; KOZWICH, DIANE L.
To: BIOCHEMICS, INC.
Reel/Frame 030643/0584 →
Continuity (3)
Continuation 12358078 · Jan 22, 2009
Provisional Application 61022708 · Jan 22, 2008
Related Publication 20130273019A1 · Oct 17, 2013